JP2009533020A5 - - Google Patents

Download PDF

Info

Publication number
JP2009533020A5
JP2009533020A5 JP2009502208A JP2009502208A JP2009533020A5 JP 2009533020 A5 JP2009533020 A5 JP 2009533020A5 JP 2009502208 A JP2009502208 A JP 2009502208A JP 2009502208 A JP2009502208 A JP 2009502208A JP 2009533020 A5 JP2009533020 A5 JP 2009533020A5
Authority
JP
Japan
Prior art keywords
seq
structural element
binding structural
amino acid
element according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009502208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009533020A (ja
JP5335662B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2007/001108 external-priority patent/WO2007110631A1/en
Publication of JP2009533020A publication Critical patent/JP2009533020A/ja
Publication of JP2009533020A5 publication Critical patent/JP2009533020A5/ja
Application granted granted Critical
Publication of JP5335662B2 publication Critical patent/JP5335662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009502208A 2006-03-27 2007-03-27 Ｇｍ−ｃｓｆ受容体に対する結合構造要素 Active JP5335662B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78656906P 2006-03-27 2006-03-27
US60/786,569 2006-03-27
PCT/GB2007/001108 WO2007110631A1 (en) 2006-03-27 2007-03-27 Binding member for gm-csf receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013002623A Division JP5665894B2 (ja) 2006-03-27 2013-01-10 Ｇｍ−ｃｓｆ受容体に対する結合構造要素

Publications (3)

Publication Number Publication Date
JP2009533020A JP2009533020A (ja) 2009-09-17
JP2009533020A5 true JP2009533020A5 (https=) 2010-05-13
JP5335662B2 JP5335662B2 (ja) 2013-11-06

Family

ID=38293698

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009502208A Active JP5335662B2 (ja) 2006-03-27 2007-03-27 Ｇｍ−ｃｓｆ受容体に対する結合構造要素
JP2013002623A Active JP5665894B2 (ja) 2006-03-27 2013-01-10 Ｇｍ−ｃｓｆ受容体に対する結合構造要素

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013002623A Active JP5665894B2 (ja) 2006-03-27 2013-01-10 Ｇｍ−ｃｓｆ受容体に対する結合構造要素

Country Status (15)

Country Link
US (8) US8263075B2 (https=)
EP (3) EP1999152B1 (https=)
JP (2) JP5335662B2 (https=)
KR (2) KR101451546B1 (https=)
CN (3) CN101443360B (https=)
BR (1) BRPI0709259B1 (https=)
CA (1) CA2647449C (https=)
DK (3) DK2423229T3 (https=)
ES (3) ES2424467T3 (https=)
MX (2) MX348827B (https=)
PL (3) PL1999152T3 (https=)
PT (3) PT2423230E (https=)
RU (2) RU2495050C2 (https=)
SI (3) SI1999152T1 (https=)
WO (1) WO2007110631A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2527590B2 (ja) 1988-02-17 1996-08-28 三洋電機株式会社 空冷式吸収冷凍機
PL1999152T3 (pl) * 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
US8075885B2 (en) 2008-04-07 2011-12-13 Kalobios Pharmaceuticals, Inc. Methods of treating heart failure using an anti-GM-CSF antibody
AU2015224416B2 (en) * 2008-12-22 2017-04-20 The University Of Melbourne Osteoarthritis treatment
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
EP3056217B1 (en) * 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2010128035A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
WO2011028697A2 (en) * 2009-09-03 2011-03-10 The Regents Of The University Of Colorado, A Body Corporate Uses of cd 116 expression level
EP2766394B1 (en) * 2011-10-10 2017-11-22 Medimmune Limited Treatment for rheumatoid arthritis
JP6426001B2 (ja) * 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
EP2602264A1 (en) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
SI2932264T1 (sl) 2012-12-14 2019-05-31 Biontech Rna Pharmaceuticals Gmbh Novi MHC-neodvisni, s tumorjem povezani antigeni
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
EP3139960B1 (en) 2014-05-07 2024-01-17 Takeda Pharmaceutical Company Limited Liquid formulation comprising gm-csf neutralizing compound
EP3145541A1 (en) * 2014-05-19 2017-03-29 Medimmune Limited Treatment for rheumatoid arthritis
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
AU2017270027B2 (en) 2016-05-24 2024-07-11 Medimmune Limited Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020096664A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
US20220010007A1 (en) 2018-11-09 2022-01-13 Kiniksa Pharmaeuticals, Ltd. Treatment for Giant Cell Arteritis
WO2020108423A1 (en) * 2018-11-27 2020-06-04 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
CN118949031A (zh) 2019-06-03 2024-11-15 基尼克萨制药股份有限公司 用gm-csf拮抗剂治疗癌症
US20230030680A1 (en) * 2020-01-07 2023-02-02 St. Jude Children's Research Hospital, Inc Chimeric gmcsf-il18 receptor
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
JP2023546657A (ja) * 2020-10-26 2023-11-07 キニクサ ファーマシューティカルズ， リミテッド Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
JP2024500747A (ja) 2020-12-18 2024-01-10 キニクサ ファーマシューティカルズ， リミテッド タンパク質組成物ならびにそれを産生及び使用するための方法
CN116887856A (zh) * 2022-01-20 2023-10-13 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991002063A1 (en) * 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
US5629283A (en) * 1989-08-11 1997-05-13 Amrad Corporation Limited Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2149881A1 (en) * 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
BRPI0108923B8 (pt) 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7282567B2 (en) * 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
PL1999152T3 (pl) * 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Similar Documents

Publication Publication Date Title
JP2009533020A5 (https=)
RU2495050C2 (ru) Связующий элемент для рецептора gm-csf
JP2008527989A5 (https=)
JP7848133B2 (ja) ヒトＩＬ－４Ｒαにおける特異的エピトープとの抗体結合及び抗体の適用
JP2011514150A5 (https=)
RU2020120539A (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
CN114502591B (zh) 靶向bcma的抗体、双特异性抗体及其用途
JP2011508592A5 (https=)
RU2009124591A (ru) Соединения
JP2012525829A5 (https=)
JP2012509881A5 (https=)
JP2015502915A5 (https=)
JP2014508511A5 (https=)
JP2014534242A5 (https=)
JP2012524071A5 (https=)
JP2015504306A5 (https=)
RU2011122720A (ru) Члены связывания против il-1r1
BR112013017951B1 (pt) Anticorpo de neutralização, sequência de dna isolada, vetor de clonagem ou expressão, processo para a produção do anticorpo, composição farmacêutica, uso de anticorpo e uso da composição farmacêutica
RS57026B1 (sr) Anti-n3pgiu amiloid beta peptid antitela i njihova upotreba
JP2021101720A5 (https=)
WO2009140348A4 (en) Anti-il-6/il-6r antibodies and methods of use thereof
JP2009225799A5 (https=)
HRP20130228T1 (hr) Antitijela s visokim afinitetom za receptor humanog il 6
JP2010524435A5 (https=)
RU2011149334A (ru) Анти-il-17f антитела и способы их применения